Akero Therapeutics, Inc. – NASDAQ:AKRO

Add to watchlist

$47.5

+19.25

+68.14%

Market open

Closed in about 3 hours

+10.01%

month

+10.01%

quarter

+16.50%

year

Market Cap	1.98B
Enterprise value	1.19B

P/E	-13.27
EV/Sales	N/A
EV/EBITDA	-7.25
Price/Sales	N/A
Price/Book	4.42
PEG ratio	-19.17
EPS	-3.2

Revenue	N/A
EBITDA	-190.80M
Income	-179.27M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Akero Therapeutics, Inc. (NASDAQ:AKRO): Profit margin
Jun 2023	0	-31.08M
Sep 2023	0	-39.65M
Dec 2023	284K	-55.18M	-19431.69%
Mar 2024	0	-53.34M

Akero Therapeutics Financials Estimate

Q Y

Akero Therapeutics, Inc. (NASDAQ:AKRO): Analyst Estimates
Mar 2024	0	-53.34M
Sep 2025	284K	-60.79M	-21408.16%
Oct 2025	0	-64.71M
Dec 2025	0	-67.24M

Analysts Price target
Financials & Ratios estimates

Akero Therapeutics, Inc. (NASDAQ:AKRO): Debt to assets
Jun 2023	663806000	47.36M	7.14%
Sep 2023	635331000	52.19M	8.22%
Dec 2023	580271000	44.96M	7.75%
Mar 2024	912243000	65.98M	7.23%

Akero Therapeutics, Inc. (NASDAQ:AKRO): Cash Flow
Jun 2023	-22.38M	-128.30M	336.85M
Sep 2023	-49.71M	-125.69M	806K
Dec 2023	-48.62M	12.78M	502K
Mar 2024	-35.14M	57.84M	366.93M

Akero Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Akero Therapeutics, Inc. (NASDAQ:AKRO): Employee count
Aug 2023	41
Sep 2023	44
Oct 2023	44
Nov 2023	44
Dec 2023	51
Jan 2024	51
Feb 2024	51
Mar 2024	55
Apr 2024	55
May 2024	55
Jun 2024	58
Jul 2024	58

Akero Therapeutics
Hedge Funds Holdings Q1 2023

30.34% -69.66%

of AKRO is owned by hedge funds

84 -75

hedge funds hold AKRO stock

11.82M -36.80M

shares is hold by hedge funds

AKRO hedge funds holdings changes

Akero Therapeutics
Insider Trading

Akero Therapeutics, Inc. (NASDAQ:AKRO): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	100332
Apr 2024	0	5000
May 2024	0	5000
Jun 2024	0	5000
Jul 2024	0	61428
Aug 2024	0	60342
Sep 2024	0	23961
Oct 2024	0	167110
Nov 2024	0	193628
Dec 2024	0	60528

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	17 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Common Stock	3,800	$19.87	$75,506
Sale	17 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Common Stock	3,800	$31.1	$118,172
Option	17 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Stock Option (Right to Buy)	3,800	$19.87	$75,506
Option	10 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Common Stock	2,450	$19.87	$48,682
Sale	10 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Common Stock	4,818	$30.91	$148,924
Option	10 Dec 2024	ROLPH TIMOTHY officer: Chief Sc..	Stock Option (Right to Buy)	2,450	$19.87	$48,682
Sale	10 Dec 2024	YOUNG JONATHAN officer: Chief Op..	Common Stock	2,503	$30.79	$77,067
Sale	10 Dec 2024	LAMY PATRICK officer: Senior VP, Commercial Strategy officer: Senior VP, Commercial ..	Common Stock	925	$30.79	$28,481
Sale	10 Dec 2024	YALE CATRIONA officer: Chief Development Officer officer: Chief Development Offi..	Common Stock	2,810	$30.79	$86,520
Sale	10 Dec 2024	WHITE WILLIAM RICHARD officer: Chief Fi..	Common Stock	2,817	$30.79	$86,735

AKRO insider trading transactions

Akero Therapeutics
Executives

Insider	Age	Compensation
Dr. Andrew Cheng (1967) Pres, Chief Executive Officer & Director	58	$849,060
Dr. Timothy Rolph (1954) Co-Founder & Chief Scientific Officer	71	$621,000
Dr. Jonathan M. Young (1970) Co-Founder, Executive Vice President, Chief Operating Officer & Sec.	55	$621,000
Mr. William R. White J.D. (1973) Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporation Devel.	52	$614,150

Akero Therapeutics
Latest News

Sunday, 29 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation	accesswire.com
Tuesday, 24 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation	accesswire.com
Sunday, 22 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out	accesswire.com
Wednesday, 18 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out	accesswire.com
Sunday, 15 December 2024
10:00	Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect	accesswire.com
Wednesday, 11 December 2024
14:00	Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation	accesswire.com
Friday, 15 November 2024
11:00	Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024	globenewswire.com
Wednesday, 13 November 2024
16:05	Akero Therapeutics to Present at the Jefferies London Healthcare Conference	globenewswire.com
Friday, 8 November 2024
07:00	Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 21 October 2024
07:00	Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024	globenewswire.com
Monday, 30 September 2024
21:37	INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm	prnewswire.com
07:00	Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference	globenewswire.com
Friday, 20 September 2024
15:37	Akero Therapeutics: Good Candidate For The MASH Basket	seekingalpha.com
Monday, 9 September 2024
07:00	Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH	globenewswire.com
Wednesday, 28 August 2024
16:05	Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference	globenewswire.com
Friday, 23 August 2024
11:46	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)	prnewswire.com
Friday, 9 August 2024
07:00	Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Wednesday, 17 July 2024
10:51	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Akero Therapeutics, Inc. (NASDAQ: AKRO)	prnewswire.com
Tuesday, 16 July 2024
13:05	Akero Therapeutics (AKRO) Moves to Buy: Rationale Behind the Upgrade	zacks.com
Friday, 28 June 2024
10:40	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm	globenewswire.com
Tuesday, 25 June 2024
10:20	AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm	businesswire.com
05:00	FINAL AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com
03:00	AKRO Today Is the Last Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit	prnewswire.com
Monday, 24 June 2024
18:59	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akero Therapeutics, Inc. (AKRO)	businesswire.com
14:06	SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Akero Therapeutics, Inc. - AKRO	prnewswire.com
13:10	AKRO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important June 25 Deadline in Securities Class Action – AKRO	globenewswire.com
13:04	Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the Firm	globenewswire.com
11:00	AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm	businesswire.com
06:00	INVESTOR DEADLINE TOMORROW: Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AKRO	accesswire.com
05:00	IMMINENT AKRO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action Lawsuit!	accesswire.com

Ideas & Opinions

Seeking Alpha 21 May 2025

Akero: FGF21 Advancement For MASH Targeting Presses On With Key Developments
Seeking Alpha 18 Apr 2025

89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Seeking Alpha 6 Apr 2025

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock
Seeking Alpha 30 Jan 2025

89bio's Pegozafermin Is Now Gaining Momentum
Seeking Alpha 28 Jan 2025

Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Seeking Alpha 8 Jul 2024

Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
Seeking Alpha 3 Apr 2024

Akero Therapeutics' EFX Data Warrants Caution
Seeking Alpha 10 Oct 2023

Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data
Seeking Alpha 10 Aug 2023

89bio, Inc.: A Big Bet On NASH
Seeking Alpha 18 May 2023

Akero Therapeutics: A Promising Solution For NASH Patients And Investors

Frequently Asked Questions (FAQ)

What's the price of Akero Therapeutics stock today?

One share of Akero Therapeutics stock can currently be purchased for approximately $47.5.
When is Akero Therapeutics's next earnings date?

Unfortunately, Akero Therapeutics's (AKRO) next earnings date is currently unknown.
Does Akero Therapeutics pay dividends?

No, Akero Therapeutics does not pay dividends.
How much money does Akero Therapeutics make?

Akero Therapeutics has a market capitalization of 1.98B.
What is Akero Therapeutics's stock symbol?

Akero Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AKRO".
What is Akero Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Akero Therapeutics?

Shares of Akero Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Akero Therapeutics's key executives?
Akero Therapeutics's management team includes the following people:
- Dr. Andrew Cheng Pres, Chief Executive Officer & Director(age: 58, pay: $849,060)
- Dr. Timothy Rolph Co-Founder & Chief Scientific Officer(age: 71, pay: $621,000)
- Dr. Jonathan M. Young Co-Founder, Executive Vice President, Chief Operating Officer & Sec.(age: 55, pay: $621,000)
- Mr. William R. White J.D. Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporation Devel.(age: 52, pay: $614,150)
Is Akero Therapeutics founder-led company?

Yes, Akero Therapeutics is a company led by its founders Dr. Timothy Rolph and Dr. Jonathan M. Young.
How many employees does Akero Therapeutics have?

As Jul 2024, Akero Therapeutics employs 58 workers, which is 5% more then previous quarter.
When Akero Therapeutics went public?

Akero Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 20 Jun 2019.
What is Akero Therapeutics's official website?

The official website for Akero Therapeutics is akerotx.com.
Where are Akero Therapeutics's headquarters?

Akero Therapeutics is headquartered at 601 Gateway Boulevard, South San Francisco, CA.
How can i contact Akero Therapeutics?

Akero Therapeutics's mailing address is 601 Gateway Boulevard, South San Francisco, CA and company can be reached via phone at +65 04876488.

Akero Therapeutics, Inc.

akerotx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

+65 04876488

601 Gateway Boulevard
South San Francisco, CA 94080

CIK: 0001744659
ISIN: US00973Y1082
CUSIP: 00973Y108